The BRĒZ Hedge.

The thesis going into Brand Spotlight Vol. 04 was simple: somewhere in the expanding cannabinoid-beverage market, somebody had to be doing what the DankeSuper Botanical Module was written to describe — pairing precise Δ9 doses with clinically-meaningful functional botanicals, building a real multi-axis effect catalog out of the combination. Functional beverage as pharmacology, not as flavor.

We checked the obvious candidates first. Cann turned out to be a pure cannabinoid-plus-flavor brand — the “botanicals” on the can are sub-clinical flavor essences (lavender, rosemary, cardamom), present at aroma doses. Wynk doesn't even gesture at botanicals. TRIP, the most likely candidate from a UK-CBD heritage standpoint, has effectively dropped cannabinoids from its US line and is now shipping a magnesium-and-flavor sparkling water rebranded as “Mindful Blend.” (We get to TRIP in the sidebar; the short version is that it has one clinically-dosed ingredient, magnesium at 120 mg, and a small constellation of others that aren't disclosed at all.)

BRĒZ is the closest thing to the real case. It's the only brand in the category actively building both halves — a precise THC line (2.5 / 5 / 10 mg tiers, minor cannabinoids called out by name) and a parallel cannabinoid-free Functional line that splits explicitly into Focus, Sleep, and Energy. Eight SKUs total. Two formulation philosophies running in parallel under one brand. From the framework's vantage, that's a genuinely interesting design.

It is also, on close reading, partly theater. The headline botanical — Lion's Mane, the brand's hero ingredient across both branches — is advertised at “2,200 mg”, which sounds significant against the 500-mg cognition-study threshold but is, on conversion, a marketing maneuver. We do the math below. The honest reading is that BRĒZ is doing more than anyone else in the category, and what they're doing still doesn't entirely add up at clinical-dose level. That's the story.

Three schools in the cannabinoid beverage market.

Before we plot BRĒZ on the matrix, it's worth situating the brand in the category. The functional-cannabinoid-beverage space currently fragments into three formulation schools, each with characteristic marketing tells and a characteristic relationship to the chemistry. They're not equally honest about what they're doing.

Two things follow. First, “functional cannabis beverage” as a category descriptor is doing a lot of work for a lot of very different products. A Cann can and a BRĒZ Flow can both get shelved under the same section header at Total Wine; they're not the same kind of object. Second, the school-3 brands are the ones whose claims actually require both modules of the DankeSuper framework to evaluate. They're also the ones most likely to overstate — because they have two marketing surfaces to leverage, not one.

BRĒZ runs two branches in parallel.

Under one brand, BRĒZ ships a THC-infused line (five SKUs, hemp-derived Δ9 per the 2018 Farm Bill) and a cannabinoid-free Functional line (three SKUs, explicitly split into Focus / Sleep / Energy). The cannabinoids and the botanicals appear in different combinations across the eight SKUs; the formulation logic is internally consistent if you read it carefully.

Two patterns are immediately visible. The cannabinoid stack on the THC-infused line is precisely disclosed — mg per cannabinoid, minor cannabinoids named, terpene (limonene) called out. The Functional line, by contrast, names a long roster of botanicals but discloses an actual mg figure for only one ingredient per SKU. Flow gets Lion's Mane in mg, Elevate gets caffeine in mg, Dream discloses nothing at the ingredient level. This is the gap between cannabinoid-grade and supplement-grade transparency, and it runs cleanly along the brand's internal product lines.

The second pattern is the cannabinoid tier structure on the THC line. BRĒZ's 2.5 / 5 / 10 mg ladder is the cleanest published example of an Altitude Control-compatible dose ladder we've seen from any single brand. Each rung is double the prior. The Cannabinoid Pharmacology Framework's altitude bands (Turtle < 2.5 mg, Tree 2.5–5, Balloon 5–10, Airplane 10–25, UFO 25+) line up almost exactly with BRĒZ's tier boundaries. The brand wasn't designed around our framework, but a brand designed thoughtfully around dose-response biology lands on roughly the same bands, which is itself a useful confirmation.

The Lion's Mane wet-weight math.

BRĒZ's Functional line headlines Lion's Mane on every SKU and on every retail case. The Flow can declares 2,200 mg of Lion's Mane on the front panel. Against the cognition-study threshold — 500 mg fruiting-body extract per day, sustained across weeks — this looks like a more-than- sufficient single-serving dose, which would be remarkable in a 12-oz beverage. On closer reading, it is not what it appears.

The fine print on BRĒZ's Lion's Mane is “33 mg of 7:1 extract from 2,200 mg wet fruiting body.” This is a three-step conversion that most consumers won't do. Mushroom “wet” weight is the raw material before drying, and Lion's Mane is roughly 90% water. A 7:1 extract means seven grams of dried raw material concentrate to one gram of extract. So the actual pharmacologically active material in a Flow can is closer to 33 mg of standardized extract, or about 231 mg of dry-equivalent fruiting body — not 2,200 mg of anything cognitively relevant.

The framework's response to this is unambiguous. Under the Botanical Module's composition math, a Lion's Mane delivery of ~46% of the clinical dose registers with an α-coefficient of approximately 0.46 of the ingredient's maximal pharmacological contribution — not zero, but not the dominant claim either. Flow gets credit for actually putting Lion's Mane in the can at a fraction that would, over weeks of repeat consumption, plausibly produce something meaningful. It does not get credit for delivering a clinical dose in one can.

This convention — expressing mushroom doses as wet-weight rather than standardized extract — is widespread in the broader supplement industry and is now creeping into cannabis-adjacent beverages. It's the analog of the supplement-aisle “5,000 mg complex” that turns out to be 50 mg of six ingredients and 4,700 mg of rice flour. We name it explicitly because cannabis is moving into adjacent categories — functional beverages, adaptogen blends, nootropic stacks — that have their own pre-existing transparency conventions, and a meaningful share of those conventions are designed to make sub-clinical doses look impressive.

The three Functional SKUs as effect-quadrant exemplars.

Setting aside the dose-disclosure issue, the formulation logic of the three Functional SKUs is structurally interesting. Each is engineered around a distinct effect quadrant, and the ingredient stacks track recognizable pharmacology even where the doses aren't published. From an editorial standpoint — the question of whether a customer reading the can can pick the right SKU for the moment — BRĒZ's three-way split is the most legible we've seen in the category.

Plotted onto the framework's quadrant geometry, the three SKUs occupy three of our four pillars in a single product line, which we haven't seen from any other brand in the category. The honest read is that Flow and Elevate each have one clinical-dose anchor that makes them real functional beverages; Dream is closer to a calming-flavor profile with positioning benefits and no disclosed pharmacology. The brand's claim — that the three SKUs map to distinct effect states — survives evaluation on the Sustained and Clarity SKUs and partially survives on Decompress.

What this means for the framework.

BRĒZ is the first brand we've plotted on both modules of the framework at the same time, and the experience of doing it surfaces three useful adjustments.

First, the Botanical Module's α-coefficient (dose-as-fraction-of-clinical) needs to be calculated against standardized extract weight, not label weight. When a brand quotes mushroom mass in wet weight, the framework should re-base to extract weight before computing the α-fraction. The current Module already does this for most ingredients (KSM-66 ashwagandha, e.g., has a 5% withanolide-standardization assumption baked in), but the wet-weight issue for fungi specifically warrants a dedicated conversion table in v1.1.

Second, the Module needs a multi-pillar SKU pattern recognized as a feature, not an error state. BRĒZ Flow ostensibly anchors in Clarity but the L-theanine + cacao stack pulls toward Calm; Elevate anchors in Sustained but cordyceps + adaptogens pull toward Calm-on-stress. We currently round to the dominant pillar. A future version should describe these as composite quadrant placements with vector-decomposed leans.

Third — and most consequentially — the BRĒZ case underscores that transparent cannabinoid disclosure and transparent botanical disclosure are not the same skill, and not the same regulatory regime. A brand can be world-class at one and industry-standard at the other under the same roof. DankeSuper's job is to make the difference legible. The framework now does that on both axes. BRĒZ is the case study that proved we needed to.

Next time, the cannabinoid-purist contrast: Cann, the brand that pioneered the cannabinoid-beverage social-drinking moment and deliberately refuses to layer functional botanicals at all. The two pieces are designed to be read together — Vol. 04 establishes what the overlay looks like at its most ambitious; Vol. 05 will establish what it looks like to refuse the overlay entirely on principle.